TransMedics Group, Inc. (TMDX) reached a significant support level, and could be a good pick for investors from a technical ...

TransMedics delivered a stellar Q1, beating revenue and EPS estimates. Click here to find out why TMDX stock is a Buy.

TransMedics Group, Inc. TMDX is well-poised for growth in the coming quarters, courtesy of its strength in OCS technology.

From the end of 2024 through the opening bell on Monday, May 12, TransMedics stock soared about 81%, and investors want to know if it can keep climbing. To find out if TransMedics is a good growth ...

TransMedics' logistics business is expanding rapidly, helping to offset a moderation in product growth. While growth is likely to moderate in the coming years, particularly as the logistics ...

TransMedics Group (NASDAQ: TMDX) has emerged as a medical devices industry leader, capturing strong growth and climbing profitability from its organ transplant delivery system. Since the company's ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

ANDOVER, Mass., April 24, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with ...

Oppenheimer has raised the price target for TransMedics from $92 to $105 with an Outperform. William Blair expresses a positive outlook on TransMedics, citing strong fourth-quarter results and a ...

Management recently raised its sales outlook for 2025. TransMedics isn't the only company with a warm perfusion device for storing and transporting organs. Shares of TransMedics Group (NASDAQ ...